The company has already established a focus on autism, eczema and insomnia.
Zelda has now engaged the services of an experienced team of clinicians and scientists to help manage its clinical trials.
Harry Karelis, executive chairman, commented:
"We welcome Dr Kuester, Dr Sasso and Ms Vergara to our research team and are delighted to have such a high calibre local team coordinating our activities in Chile.
"Zelda is steadily progressing towards commencement of its clinical trial program in Chile and I look forward to providing shareholders positive updates in due course."
Zelda has strategically focused on conducting its research activities in Chile due to the efficiency of its legal and regulatory framework, cost effectiveness and its market access into the large South American pharmaceutical market.
The Chilean government granted permission for the first cannabis crop to be planted for medicinal purposes in 2015, and has subsequently allowed the sale of medicinal cannabis in pharmacies.
This has given rise to researchers and organisations specialising in medicinal cannabis treatments.
Zelda has capitalised on this, forming strategic alliances with world-class researchers and physicians, and has access to valuable patient data which will assist in the development of robust clinical trials.